Clinical Trials Logo

Osteoporosis, Postmenopausal clinical trials

View clinical trials related to Osteoporosis, Postmenopausal.

Filter by:

NCT ID: NCT03761979 Completed - Osteopenia Clinical Trials

Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults

Start date: March 9, 2017
Phase: N/A
Study type: Interventional

No clinical trials have evaluated strontium L-lactate (SrLac), the strontium salt of the L-enantiomer of lactic acid. Therefore, this clinical study was conducted to obtain general safety and pharmacokinetic (PK) information following acute oral intakes of three doses of SrLac by healthy adults. The data provided valuable comparisons with the pharmacokinetics of other strontium salts that are in clinical use and allowed determination of the dose of SrLac that will be useful for the management of bone health.neficial for the treatment of low bone density of osteoporosis and osteopenia.

NCT ID: NCT03742362 Not yet recruiting - Clinical trials for Osteoporosis, Postmenopausal

MRI Study of the Distal Radius Bone Marrow Fat Fraction in Osteoporotic and Healthy Women

Start date: November 15, 2018
Phase: N/A
Study type: Interventional

The aim of the study is to test whether the distal radius bone marrow show significant difference in the fat fraction in young women compared to post menopausal women with and without osteoporosis.

NCT ID: NCT03720886 Active, not recruiting - Clinical trials for Postmenopausal Osteoporosis

G56W1 in Women With Postmenopausal Osteoporosis

Start date: October 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the pharmacokinetics and safety and explore therapeutic effects with once-weekly recombinant human parathyroid hormone for injection ( 1-34 ) ( G56W1 ) in women with post-menopausal osteoporosis .The anticipated time on study treatment is 24 weeks, and the target sample size is 148 individuals.

NCT ID: NCT03710889 Recruiting - Osteoporosis Clinical Trials

Early Effects of Abaloparatide on Tissue-based Indices of Bone Formation and Resorption

Start date: September 20, 2018
Phase: Phase 3
Study type: Interventional

Effects of abaloparatide on bone formation and resorption in postmenopausal women with osteoporosis.

NCT ID: NCT03701113 Recruiting - Clinical trials for Osteoporosis, Postmenopausal

Milk Protein and Bone Health in Postmenopausal Women

Start date: October 22, 2018
Phase: N/A
Study type: Interventional

The process of bone remodeling exhibits pronounced diurnal pattern that is important for bone health. A balanced rate of bone resorption is required to maintain bone health, a balance that can be disturbed during the life-cycle to effect net rate of formation (as occurs during growth and development to adulthood) or net resorption (as occurs, for example, during the menopause). Bone turnover is a nutritionally modulated process and the investigators believe a milk-based protein supplement (MBPS) can modulate beneficially the rate of bone resorption over the time period when bone remodeling is most active i.e. late evening/overnight. In this novel approach to the timing of nutrient ingestion, the proposed nutrient intervention seeks to modify (reduce) the rate of bone resorption and promote the rate of bone formation to the benefit of bone health in this at risk population..

NCT ID: NCT03692143 Active, not recruiting - Quality of Life Clinical Trials

Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP

Start date: January 1, 2017
Study type: Observational

This study aimed to compare teriparatide treatments and PVPs, focusing on its effects on life qualities and effect/coast ratio and evaluate which method is better for patients.

NCT ID: NCT03623633 Not yet recruiting - Osteoporosis Clinical Trials

Comparative Antiresorptive Efficacy Discontinuation of Denosumab

Start date: September 1, 2018
Phase: Phase 4
Study type: Interventional

Osteoporosis remains a significant healthcare burden for the United States. Current FDA-approved osteoporosis treatments include teriparatide, abaloparatide, bisphosphonates, denosumab, and raloxifene. Denosumab is a fully human monoclonal antibody that specifically binds to receptor activator of nuclear factor kappa-B ligand (RANKL). Denosumab potently suppresses osteoclastic activity but bone turnover rapidly normalizes and bone turnover marker levels can rebound above baseline levels after the drug is discontinued. The proposed study will help us determine the relative efficacy of two oral antiresorptive medications that are FDA-approved for treatment of postmenopausal osteoporosis (alendronate and raloxifene) in preventing the rebound increase in bone turnover that occurs after denosumab discontinuation.

NCT ID: NCT03563235 Not yet recruiting - Clinical trials for Postmenopausal Osteoporoses

Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules

Start date: September 1, 2018
Phase: Early Phase 1
Study type: Interventional

Osteoporosis is a common senile disease with a high incidence. The Chinese medicine differentiation treatment has small side effects and can be taken for a long time, which has certain advantages. This project adopts the experience of the person in charge of the project-Xulin Jiangu Granules and clinically collects patients with postmenopausal osteoporosis (kidney deficiency and blood stasis syndrome).

NCT ID: NCT03512743 Enrolling by invitation - Clinical trials for Postmenopausal Osteoporosis

Association of Serum Ferritin and Bone Mineral Density With Bone Metabolism in Chinese Healthy Postmenopausal Women

Start date: May 1, 2018
Study type: Observational

Large amounts of experimental and animal evidence have confirmed that iron accumulation is associated with bone loss. However, it is still lack of the clinical studies relating iron accumulation to bone loss, especially in the pathological conditions during our Chinese. In this study, the investigators aim to assess the association between the levels of serum ferritin and bone mineral density in Chinese healthy postmenopausal women.

NCT ID: NCT03475719 Enrolling by invitation - Clinical trials for Osteoporosis, Postmenopausal

A Clinical Trial to Evaluate the Safety and Pharmacokinetic

Start date: January 11, 2018
Phase: Phase 1
Study type: Interventional

A phase 1 clinical trail to evaluate the safety and pharmacokinetic characteristic after administration of fixed-dose combination or loose combination of HUG186 in healthy adult male or menopausal female volunteers